Evidence map›Paper›PMID 38089507›Full record

ReviewTaiwan journal of ophthalmology

Peripheral defocus as it relates to myopia progression: A mini-review.

Nir Erdinest, Naomi London, Itay Lavy, David Berkow, David Landau, Nadav Levinger, Yair Morad

Open access · diamondAbstract readReview
In one paragraph

Review in Taiwan journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Astaxanthin (AstaRealAdvances in therapy · 2025
    Trial
  2. Article
  3. Article
  4. RLRL Therapeutic Feasibility and Potential Mechanism on Myopia.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Nir ErdinestDepartment of Opthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Naomi LondonNaomi Vision Boutique, Jerusalem, Israel.
Itay LavyDepartment of Opthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
David BerkowOptometry and Vision Science, Aston University, Birmingham, UK.
David LandauDepartment of Opthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Nadav LevingerDepartment of Opthalmology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Yair MoradThe Myopia Center, Rishon LeZion, Israel.
Hadassah Medical Center · ILAssaf Harofeh Medical Center · ILAston University · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myopia is the most common refractive error in the world and has reached a pandemic level. The potential complications of progressive myopia have inspired researchers to attempt to understand the sources of myopia and axial elongation and to develop modalities to arrest progression. Considerable attention has been given over the past few years to the myopia risk factor known as hyperopic peripheral blur, which is the focus of this review. It will discuss the primary theories believed to be the cause of myopia and the parameters considered to contribute to and influence the effect of peripheral blur, such as the surface retinal area of blur or the depth of blur. The multitude of optical devices designed to provide peripheral myopic defocus will be mentioned, including bifocal and progressive addition ophthalmic lenses, peripheral defocus single-vision ophthalmic lenses, orthokeratology lenses, and bifocal or multifocal center distance soft lenses, as well as their effectivity as discussed in the literature to date.

Indexed as

Hyperopic peripheral blurmyopiaperipheral defocus

Identifiers

PMID38089507
PMCPMC10712741
OpenAlexW4315647859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.